Focus on Pathways: Targeting the CSF-1R Pathway in Graft-vs-Host Disease
Hannah Choe, MD discusses the role of the CSF-1 receptor (CSF-1R) pathway in the pathogenesis of graft-versus-host disease (GVHD) and other diseases. She reviews the rationale for targeting this pathway as a therapeutic strategy and examines preclinical and clinical data on the use of CSF-1R inhibitors, such as axatilimab, for the treatment of GVHD. Dr. Choe provides insights on the practical considerations for integrating these novel agents into clinical practice.
EP. 1: Graft-Versus-Host Disease: Pathogenesis, Clinical Challenges, and Unmet Treatment Needs
July 8th 2024In this video, Dr. Hannah Choe provides an overview of the background of graft-versus-host disease (GVHD), discusses currently approved treatments and their limitations, and the significant unmet treatment needs in GVHD.
EP. 2: The CSF-1R Signaling Pathway in GVHD and Investigational Agents Targeting this Pathway
July 8th 2024Dr. Choe discusses the potential role of the CSF-1R signaling pathway in the pathogenesis of numerous diseases, including GVHD. A video segment explores how dysregulation of this pathway can contribute to the development and progression of GVHD, providing the rationale for targeting CSF-1R as a potential therapeutic strategy.
EP. 3: AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD
July 17th 2024Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.
EP. 4: Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHD
July 17th 2024Dr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.
